Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050
Publication date
2019-03
Authors
Tonneijck, Lennart
Smits, Mark
Muskiet, Marcel H A
Hoekstra, Trynke
Kramer, Mark H H
Danser, A H Jan
Ter Wee, Piet M
Diamant, Michaela
Joles, Jaap A.
van Raalte, Daniel H
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Taverne, Advanced and Specialised Nursing, Internal Medicine, Endocrinology, Diabetes and Metabolism, Published Erratum, Journal Article
Citation
Tonneijck, L, Smits, M M, Muskiet, M H A, Hoekstra, T, Kramer, M H H, Danser, A H J, Ter Wee, P M, Diamant, M, Joles, J A & van Raalte, D H 2019, 'Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes : A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050', Diabetes Care, vol. 42, no. 3, pp. 494. https://doi.org/10.2337/dc19-er03